January 8, 2019 09:26 AM EST
R&D

Liz Bar­ret­t's bet on Uro­Gen proves time­ly, as biotech's lead drug scores in key study

Natalie Grover

Reporter

Fresh off the high of poach­ing No­var­tis on­col­o­gy group head Liz Bar­rett in­to tak­ing charge of the small biotech, Uro­Gen Phar­ma $URGN on Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times